Since its initial public offering, Convatec has followed a familiar playbook to press its advantage in advanced wound care and to enhance its ostomy business. By and large, we like Convatec’s ...

This means that over the past quarter there has been an increase of insiders selling their shares ... and marketing of an insulin infusion system for people with insulin-dependent diabetes. It ...

Analyst Josh Jennings of TD Cowen reiterated a Buy rating on Insulet (PODD – Research Report), retaining the price target of $264.00.

Managing stress and maintaining overall health can be quite challenging in today’s fast-paced world. Many people turn to ...

Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsLarry Heaton – Chief Executive OfficerMike ...

More than 800 million adults have diabetes worldwide – almost twice as many as previous estimates have suggested – and more ...

AdaptHealth Corp. (NASDAQ:AHCO – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the six ...

AdaptHealth (NASDAQ:AHCO – Free Report) had its target price reduced by Robert W. Baird from $16.00 to $14.00 in a report ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...